Stereotactic biopsy is often performed for diagnostic purposes before treat
ing patients whose imaging studies highly suggest glioma, Indications cited
for biopsy include diagnosis and/or the "inoperability" of the tumor. This
study questions the routine use of stereotactic biopsy in the initial mana
gement of gliomas, At The University of Texas M, D, Anderson Cancer Center,
we retrospectively reviewed a consecutive series of 81 patients whose imag
ing studies suggested glioma and who underwent stereotactic biopsy followed
by craniotomy/resection (within 60 days) between 1993 and 1998. All releva
nt clinical and imaging information was reviewed, including computerized vo
lumetric analysis of the tumors based on pre- and postoperative MRI. Stereo
tactic biopsy was performed at institutions other than M, D, Anderson in 78
(96%) of 81 patients. The majority of tumors were located either in eloque
nt brain (36 of 81 = 44%) or near-eloquent brain (41 of 81 = 51%), and this
frequently was the rationale cited for performing stereotactic biopsy. Gro
ss total resection (> 95%) was achieved in 46 (57%) of 81 patients, with a
median extent of resection of 96% for this series. Diagnoses based on biops
y or resection in the same patient differed in 40 (49%) of 82 cases. This d
iscrepancy was reduced to 30 (38%) of 80 cases when the biopsy slides were
reviewed preoperatively by each of three neuropathologists at M, D, Anderso
n, Major neurologic complications occurred in 10 (12.3%) of 81 surgical pat
ients and 3 (3.7%) of 81 patients undergoing biopsy. Surgical morbidity was
probably higher in our series than it would be for glioma patients in gene
ral because our patients represent a highly selected subset of glioma patie
nts whose tumors present a technical challenge to remove. Stereotactic biop
sy is frequently inaccurate in providing a correct diagnosis and is associa
ted with additional risk and cost. If streotactic biopsy is performed, expe
rt neuropathology consultation should be sought.